CellRight Technologies Signs Multi-Year Distribution Agreement With Arthrex, Inc.
07 March 2018 - 12:13AM
Business Wire
Tissue Regenix Group (AIM:TRX) (“Tissue Regenix” or “The Group”)
the regenerative medical devices company today announces subsidiary
CellRight Technologies (“CellRight”) has signed a long-term,
multi-year distribution agreement with Arthrex, Inc., a premier
innovator of orthopaedic surgical solutions.
CellRight, which produces industry leading verified
osteobiologics for use in orthopaedic, spine and foot and ankle
procedures, enhances the healing opportunities of defects caused by
trauma and disease.
The multi-year commitment will give surgeons access to verified
osteobiologics and advanced surgical instrumentation and techniques
to help influence better patient outcomes.
“This long-term distribution agreement will allow physicans and
patients better access to CellRight’s innovative orthobiologics
through the Arthrex network,” said Jesus Hernandez, CEO for
CellRight Technologies. Our shared vision of offering surgeons
total solutions which can positively impact patient outcomes
solidifies the decision of both companies to work together.”
Steve Couldwell, CEO Tissue Regenix Group plc commented: “This
is a flagship distribution agreement for CellRight and the wider
Tissue Regenix Group. It highlights the value of strategic
partnerships with prestigious companies in this space. We look
forward to working with Arthrex to bring the CellRight product
portfolio to an extended network of healthcare professionals.”
CellRight Technologies and TRX Orthopedics, will be exhibiting
at the American Academy of Orthopaedic Surgeons in New Orleans,
March 7-10 and can be found at booth #5413.
About Tissue Regenix
Tissue Regenix is a leading medical devices company in the field
of regenerative medicine. Tissue Regenix was formed in 2006 when it
was spun-out from the University of Leeds, UK. The company's
patented decellularisation ('dCELL®') technology removes DNA and
other cellular material from animal and human soft tissue leaving
an acellular tissue scaffold which is not rejected by the patient's
body and can then be used to repair diseased or worn out body
parts. Current applications address many critical clinical needs
such as sports medicine, heart valve replacement and wound
care.
In November 2012 Tissue Regenix Group plc set up a subsidiary
company in the United States - 'Tissue Regenix Wound Care Inc.',
rebranded TRX BioSurgery in February 2018. January 2016 saw the
establishment of joint venture GBM-V, a multi- tissue bank
based in Rostock, Germany.
In August 2017 Tissue Regenix acquired CellRight Technologies®,
a biotech company that specializes in regenerative medicine and is
dedicated to the development of innovative osteoinductive and wound
care scaffolds that enhance healing opportunities of defects
created by trauma and disease. CellRight's human osteobiologics may
be used in spine, trauma, general orthopedic, foot & ankle,
dental, and sports medicine surgical procedures.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180306005983/en/
Tissue Regenix Group plcCaitlin Pearson Head of
CommunicationsTel: (+44) 330 430 3073 / 07920272 441orFTI
ConsultingBrett Pollard / Mo Noonan/ Rob WinderTel: 0203 727
1000
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From Apr 2024 to May 2024
Tissue Regenix (LSE:TRX)
Historical Stock Chart
From May 2023 to May 2024